Announced Tue, 1 Sept · 16:40 IST
Venmax Drugs submits FY26 Annual Report; AGM on September 26, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-6.7%1-day move
₹15.48
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-6.7-8.3+0.6-3.6-1.9+0.1————
Up moveDown movePending
AI summary
Venmax Drugs filed its 37th Annual Report for FY26 with BSE. AGM is on September 26, 2026 at 12:30 PM via video conferencing. Sales surged to Rs 802.49 lakhs from Rs 80.73 lakhs, with profit after tax of Rs 24.82 lakhs versus a loss of Rs 1.05 lakhs. No dividend declared. Key items: Venkata Rao Sadhanala redesignated as Managing Director at Rs 30 lakhs per year, plus two new director appointments. Paid-up capital rose to Rs 11.58 crores from warrant conversions.
Likely market impact
Strong sales recovery and return to profit are positives. No dividend may disappoint income investors. Dilution from warrant conversions is a watch point.